Современные тенденции в лечении острой сенсоневральной тугоухости

1. Chandrasekhar SS. Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. Otol Neurotol 2001; 22 (1): 18–23.
2. Alexiou C et al. Sudden sensorineural hearing loss. Does application of glucocorticoids make sense? Arch Otolaryngol Head Neck Surg 2001; 127 (3): 253–8.
3. Mattox DE, Simmons FB. Natural history of sudden sensorioneural hearing loss. Ann Otol 1977; 86 (4 Pt 1): 463–80.
4. Nordang L. Laurent C, Mollnes TE. Complement activation in sudden deafness. Arch Otolaryngol Head Neck Surg 1998; 124 (6): 633–6.
5. Fujimura T et al. Hyperbaric oxygen and steroid therapy for idiopathic sudden sensorineural hearing loss. Eur Arch Otorhinolaryngol 2007; 264 (8): 861–6.
6. Lefebvre PP, Staecker H. Steroid perfusion of the inner ear for sudden sensorineural hearing loss after failure of conventional therapy: a pilot study. Acta Otolaryngol 2002; 122 (7): 698–702.
7. Zhao H et al. Prognostic factors for patients with the idiopathic sudden sensorineural hearing loss. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2008; 43 (9): 660–4.
8. Zivic L, Zivic D, Stojanovic S. Sudden hearing loss – our experience in treatment with vasoactive therapy. Srp Arh Celok Lek 2008; 136 (3–4): 91–4.
9. Probst R et al. A randomized, double-blind, placebo-controlled study of dextran-pentoxifylline medication in acute acoustic trauma and sudden hearing loss. Acta Otolaryngol 1992; 112 (3): 435–43.
10. Burschka MA et al. Effect of treatment with Ginkgo biloba extract EGb 761 (oral) on unilateral idiopathic sudden hearing loss in a prospective randomized double-blind study of 106 outpatients. Eur Arch Otorhinolaryngol 2001; 258 (5): 213–9.
11. Reisser CH, Weidauer H. Ginkgo biloba extract EGb 761 or pentoxifylline for the treatment of sudden deafness: a randomized, reference-controlled, double-blind. Acta Otolaryngol 2001; 121 (5): 579–84.
12. Kronenberg J et al. Vasoactive therapy versus placebo in the treatment of sudden hearing loss: a double-blind clinical study. Laryngoscope 1992; 102 (1): 65–8.
13. Uri N et al. Acyclovir in the treatment of idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2003; 128 (4): 544–9.
14. Stokroos RJ, Albers FWJ, Tenvergert EM. Antiviral treatment of idiopathic sudden sensorineural hearing loss: a prospective, randomized, double-blind clinical trial. Acta Otolaryngol 1998; 118 (4): 488–95.
15. Westerlaken BO et al. Treatment of idiopathic sudden sensorineural hearing loss with antiviral therapy: a prospective, randomized, double-blind clinical trial. Ann Otol Rhinol Laryngol 2003; 112 (11): 993–1000.
16. Tucci DL et al. Treatment of sudden sensorineural hearing loss with systemic steroids and valacyclovir. Otol Neurotol 2002; 23 (3): 301–8.
17. Conlin AE, Parnes LS. Treatment of sudden sensorineural hearing loss. I. A systematic review. Arch Otolaryngol Head Neck Surg 2007; 133 (6): 573–81.
18. Wilson WR, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss. Arch Otolaryngol Head Neck Surg 1980; 106 (12): 772–6.
19. Cinamon U, Bendet E, Kronenberg J. Steroids, carbogen or placebo for sudden hearing loss: a prospective double-blind study. Eur Arch Otorhinolaryngol 2001; 258 (9): 477–80.
20. Moskowitz D, Lee KJ, Smith HW. Steroid use in idiopathic sudden sensorineural hearing loss. Laryngoscope 1984; 94 (5 Pt 1): 664–6.
21. Veldman JE, Hanada T, Meeuwsen F. Diagnostic and therapeutic dilemmas in rapidly progressive sensorineural hearing loss and sudden deafness. Acta Otolaryngol (Stockh) 1993; 113 (3): 303–6.
22. Kitajiri S et al. Is corticosteroid therapy effective for sudden-onset sensorineural hearing loss at lower frequencies? Arch Otolaryngol Head Neck Surg 2002; 128 (4): 365–7.
23. Garcia-Berrocal JR et al. Adverse effects of glucocorticoid therapy for inner ear disoders. ORL J Otorhinolaryngol Relat Spec 2008; 70 (4): 271–4.
24. Buhrer M, Frey FJ, Frey BM. Prednisolone concentrations in cerebrospinal fluid after different prednisolone prodrugs. Br J Pharmacol 1991; 31 (1): 111–3.
25. Parnes LS, Sun AH, Freemann DJ. Corticosteroids pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 1999; 109 (7 Pt 2): 1–17.
26. Barany R. Die Beeinflussung des Ohrensausens durch intravenos injizierte Localanasthetica. Acta Otolaryngol 1935; 23: 201–7.
27. Schuknecht HF. Ablation therapy for the relief of Meniere’s disease. Laryngoscope 1956; 66: 859–70.
28. Bryant FL. Intratympanic injection of steroid for treatment of facial paralysis. Laryngoscope 1973; 83 (5): 700–6.
29. Herr BD, Marzo SJ. Intratympanic steroid perfusion for refractory sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2005; 132 (4): 527–31.
30. Slattery WH et al. Intratympanic steroid injection for treatment of idiopathic sudden hearing loss. Otolaryngol Head Neck Surg 2005; 133 (2): 251–9.
31. Banerjee A, Parnes LS. Intratympanic corticosteroids for sudden idiopathic sensorineural hearing loss. Otol Neurotol 2005; 26 (5): 878–81.
32. Gouveris H, Selivanova O, Mann W. Intratympanic dexamethasone with hyaluronic acid in the treatment of idiopathic sudden sensorineural hearing loss after failure of intravenous steroid and vasoactive therapy. Eur Arch Otorhinolaryngol 2005; 262 (2): 131–4.
33. Shi J et al. Intratympanic dexamethasone medication for sudden sensorineural hearing loss: clinical evaluation. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2006; 20 (16): 749–51.
34. Kilic R et al. Intratympanic methylprednosolone for sudden sensorineural hearing loss. Otol Neurotol 2007; 28 (3): 312–6.
35. Shirwany NA, Seidman MD, Tang W. Effect of transtympanic injection of steroids on cochlear blood flow, auditory sensitivity, and histology in the guinea pig. Am J Otol 1998; 19 (2): 230–5.
36. Lange G, Maurer J, Mann W. Long-term results after interval therapy with intratympanic gentamicin for Meniere’s disease. Laryngoscope 2004; 114 (1): 102–5.
37. Thomsen J, Charabi S, Tos M. Preliminary results of a new delivery system for gentamicin to the inner ear in patients with Meniere’s disease. European archives of oto-rhino-laryngology 2000; 257 (7): 362–5.
38. Schoendorf J, Neugebauer P, Michel O. Continuous intratympanic infusion of gentamicin via a microcatheter in Meniere’s disease. Otolaryngol Head Neck Surg 2001; 124: 203–7.
39. Salt AN. Simulation of methods for drug delivery to the cochlear fluids. Adv Otorhinolaryngol 2002; 59: 140–8.
40. Salt AN, Ma Y. Quantification of solute entry into cochlear perilymph through the round window membrane. Hear Res 2001; 154 (1–2): 88–97.
41. Salt AN, Plontke SK. Local inner-ear drug delivery and pharmakokinetiks. Drug Discovery Today 2005; 10 (19): 1299–306.
42. Plontke SK et al. Cochlear pharmacokinetics with local inner ear drug delivery using a three-dimensional finite-element computer model. Audiol Neurotol 2007; 12 (1): 37–48.
43. Plontke SK et al. Dexamethasone concentration gradients along scala tympani after application to the round window membrane. Otol Neurotol 2008; 29 (3): 401–6.
44. Plontke S et al. Technical Note on Microcatheter Implantation for Local Inner Ear Drug Delivery: Surgical Technique and Safety Aspects. Otol Neurotol 2006; 27 (7): 912–7.
45. Goycoolea MV. Clinical aspects of round window membrane permeability under normal and pathological conditions. Acta Otolaryngol 2001; 121 (4): 437–47.
46. Battista RA. Intratympanic dexamethasone for profound idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2005; 132 (6): 902–5.
47. Choung YH et al. Intratympanic dexamethazone injection for refractory sudden sensorineural hearing loss. Laryngoscope 2006; 116 (5): 747–52.
48. Plontke S et al. Outcomes research analysis of continuous intratympanic glucocorticoid delivery in patients with acute severe to profound hearing loss: basis for planning randomized controlled trials. Acta Otolaryngol 2005; 125 (8): 830–9.
49. Plontke S et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope 2009; 119: 359–69.
50. Plaza G, Herraiz C. Intratympanic steroids for treatment of sudden hearing loss after failure of intravenous therapy. Otolaryngol Head Neck Surg 2007; 137 (1): 74–8.
51. Ho HG et al. Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope 2004; 114 (7): 1184–9.
52. Ahn JH et al. Therapeutic effectiveness over time of intratympanic dexamethasone as salvage treatment of sudden deafness. Acta Otolaryngol 2008; 128 (2): 128–31.
53. Peng Y et al. Clinical investigation of different routes of administration of dexamethasone on sudden deafness. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2008; 22 (10): 442–5.
54. Kakehata S et al. Comparison of intratympanic and intravenous dexamethasone treatment of sudden sensorineural hearing loss with diabetes. Otol Neurotol 2006; 27 (5): 604–8.
55. Hong S, Park C, Lee J. Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngol Head Neck Surg 2009; 141: 579–83.
56. Spear S, Schwartz S. Intratympanic Steroids for Sudden Sensorineural Hearing Loss: A Systematic Review. Otolaryngol Head and Neck Surg 2011; 145 (4): 534–43.

А.Г.Атанесян

ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москва

________________________________________________

A.G.Atanesian